A number of other equities analysts also recently weighed in on the stock. Jefferies Group lifted their target price on shares of GlaxoSmithKline plc from GBX 1,900 ($23.16) to GBX 1,950 ($23.77) and gave the stock a buy rating in a research note on Thursday, October 13th. Deutsche Bank AG reissued a hold rating and set a GBX 1,870 ($22.79) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, October 12th. Citigroup Inc. reissued a buy rating and set a GBX 1,800 ($21.94) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, October 5th. BNP Paribas reissued an underperform rating and set a GBX 1,520 ($18.53) target price on shares of GlaxoSmithKline plc in a research note on Friday, September 30th. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline plc in a research note on Thursday, September 22nd. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of GBX 1,687.13 ($20.56).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1673.00 on Monday. The company’s market capitalization is GBX 81.32 billion. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56. The firm’s 50-day moving average is GBX 1,651.06 and its 200 day moving average is GBX 1,566.16.
The company also recently disclosed a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were paid a dividend of GBX 19 ($0.23) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.12%.
In other GlaxoSmithKline plc news, insider Witty,Sir Andrew P sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.63), for a total value of £169,300 ($206,337.60). Also, insider Slaoui,Moncef purchased 28 shares of the business’s stock in a transaction on Friday, August 12th. The stock was bought at an average cost of GBX 2,208 ($26.91) per share, with a total value of £618.24 ($753.49).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.